ロード中...
Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis
PURPOSE: To investigate the safety and efficacy of the combination of lenalidomide and prednisone in patients with myelofibrosis (MF). PATIENTS AND METHODS: Forty patients with MF were treated. Therapy consisted of lenalidomide 10 mg/d (5 mg/d if baseline platelet count < 100 × 10(9)/L) on days 1...
保存先:
| 出版年: | J Clin Oncol |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Clinical Oncology
2009
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4879697/ https://ncbi.nlm.nih.gov/pubmed/19720904 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.22.6548 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|